2012 - Fellow of Alfred P. Sloan Foundation
Internal medicine, Cervical cancer, Immunology, Gynecology and Risk factor are his primary areas of study. Matti Lehtinen interconnects Endocrinology and Oncology in the investigation of issues within Internal medicine. The concepts of his Cervical cancer study are interwoven with issues in Serology and Vaccine efficacy, Vaccination.
His studies in Vaccination integrate themes in fields like Public health and Human papillomavirus. His research integrates issues of Sexually transmitted disease and Virology in his study of Immunology. His Risk factor research integrates issues from Odds ratio, Cancer, Chlamydia trachomatis, Case-control study and Prospective cohort study.
His primary areas of investigation include Internal medicine, Immunology, Vaccination, Cervical cancer and Virology. Internal medicine is closely attributed to Oncology in his work. His Vaccination study combines topics from a wide range of disciplines, such as Incidence, HPV infection and Human papillomavirus.
His Cervical cancer research includes elements of Cancer registry, Gynecology and Clinical trial. The Virology study combines topics in areas such as Epitope, Antigen and Molecular biology. In his research on the topic of Risk factor, Pregnancy is strongly related with Case-control study.
His scientific interests lie mostly in Vaccination, Internal medicine, Human papillomavirus, Randomized controlled trial and Cervical cancer. His Vaccination research is multidisciplinary, incorporating elements of Young adult, Cervical intraepithelial neoplasia and Incidence. Matti Lehtinen has included themes like Gynecology, Vaccine trial, Immunology and HPV infection in his Cervical intraepithelial neoplasia study.
His Internal medicine research focuses on subjects like Oncology, which are linked to Ovarian cancer and Risk factor. The study incorporates disciplines such as Disease and Artificial intelligence in addition to Cervical cancer. Matti Lehtinen focuses mostly in the field of Cohort, narrowing it down to topics relating to HPV vaccines and, in certain cases, Antibody.
His primary areas of study are Vaccination, Internal medicine, Vaccine efficacy, Cervical cancer and Randomized controlled trial. Immunology covers Matti Lehtinen research in Vaccination. In his work, Risk factor and Cancer is strongly intertwined with Oncology, which is a subfield of Internal medicine.
His research in Vaccine efficacy tackles topics such as Herd immunity which are related to areas like Papillomavirus Vaccines, Herd and Human papillomavirus. Matti Lehtinen combines subjects such as Mass screening, Cancer prevention and Environmental health with his study of Cervical cancer. While the research belongs to areas of Cervical intraepithelial neoplasia, he spends his time largely on the problem of HPV infection, intersecting his research to questions surrounding Colposcopy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa;Gonzalo Perez;Susanne K. Kjaer;Jorma Paavonen.
The New England Journal of Medicine (2007)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler.
The Lancet (2009)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud.
The Lancet (2007)
Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck
Mork J;Lie Ak;Glattre E;Hallmans G.
The New England Journal of Medicine (2001)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn.
Lancet Oncology (2012)
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Luisa L. Villa;Kevin A. Ault;Anna R. Giuliano;Ronaldo L.R. Costa.
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
Tarja Anttila;Pekka Saikku;Pentti Koskela;Aini Bloigu.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler;Xavier Castellsagué;Suzanne M. Garland;Anne Szarewski.
Lancet Oncology (2012)
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.
Pentti Tuohimaa;Leena Tenkanen;Merja Ahonen;Sonja Lumme.
International Journal of Cancer (2004)
Seroepidemiology of the human polyomaviruses.
Annika Stolt;Kestutis Sasnauskas;Pentti Koskela;Matti Lehtinen.
Journal of General Virology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: